Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results

US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years

https://ift.tt/YoZqMNT